


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

EXPRESS MAIL LABEL NUMBER: EV 318 739 991 US

DATE OF DEPOSIT: October 20, 2003

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.


JASON BERRY

**CONTINUATION
APPLICATION**

for

UNITED STATES LETTERS PATENT

on

**FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS (FHF_s) AND METHODS
OF USE**

by

Jeremy Nathans

and

Phillip M. Smallwood

Sheets of Drawings: Twenty Four (24)

Docket No.: JHU1380-2

Lisa A. Haile, J.D., Ph.D.
Gray Cary Ware & Freidenrich LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133

FIBROBLAST GROWTH FACTOR
HOMOLOGOUS FACTORS (FHF's) AND METHODS OF USE

BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

5 The invention relates generally to polypeptide growth factors and specifically to fibroblast growth factor homologous factors (FHF's) and nucleic acids encoding FHF's.

2. DESCRIPTION OF RELATED ART

10 The fibroblast growth factor (FGF) family encompasses a group of structurally related proteins with a wide range of growth promoting, survival, and differentiation activities *in vivo* and *in vitro* (reviewed in Baird and Gospodarowicz, *N.Y. Acad. Sci.*, 638:1, 1991; Eckenstein, *J. Neurobiology*, 25:1467, 1994; Mason, *Cell*, 78:547, 1994). As of June, 1996, nine members of this family had been characterized by molecular cloning and their sequences published. The first two members of the family to be characterized, acidic FGF (aFGF/FGF-1) and basic FGF (bFGF/FGF-2), have been found in numerous tissues, including brain, eye,
15 kidney, placenta, and adrenal tissues (Jaye, *et al.*, *Science*, 233:541, 1986; Abraham, *et al.*, *Science*, 233:545, 1986). These factors have been shown to be potent mitogens and survival factors for a variety of mesoderm and neuroectoderm-derived tissues, including fibroblasts, endothelial cells, hippocampal and cerebral cortical neurons, and astroglia (Burgess and Maciag, *Ann. Rev. Biochemistry*, 58:575, 1989). Another member of the FGF family is int-
20 2/FGF-3, which is encoded by a gene that is a common target for activation by the mouse

mammary tumor virus, and therefore is presumed to be an oncogenic factor (Smith, *et al.*, *EMBO J.*, 7:1013, 1988). The genes encoding FGF-4, FGF-5, and FGF-6 have transforming activity when introduced into NIH 3T3 cells (Delli-Bovi, *et al.*, *Cell*, 50:729, 1987; Zhan, *et al.*, *Mol. Cell. Biol.*, 8:3487, 1988; Marics, *et al.*, *Oncogene*, 4:335, 1989), while
5 keratinocyte growth factor (KGF)/FGF-7, FGF-8, and FGF-9 are mitogenic for keratinocytes, mammary carcinoma cells, and astrocytes, respectively (Finch, *et al.*, *Science*, 245:752, 1989; Tanaka, *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:8928, 1992; Miyamoto, *et al.*, *Mol. Cell Biol.*, 13:4251, 1993). Recent experiments indicate that several FGFs have bioactivities that were not evident during their initial identification. For example,
10 FGF-2 has been shown to induce ventral mesoderm in *Xenopus* embryos (Slack, *et al.*, *Nature* 326:197-200, 1987; Kimmelman, *et al.*, *Cell* 51:869-877, 1989), FGF-4 has been shown to be involved in growth and patterning of the chick limb bud (Niswander, *et al.*, *Nature* 371:609-612, 1994), FGF-5 has been shown to control hair follicle cycling in the mouse (Hebert, *Cell* 78:1017-1025, 1994), and FGF-8 has been shown to cause duplications
15 of the embryonic chick midbrain (Crossley, *et al.*, *Nature* 380:66-68, 1996). Several of the FGFs, including aFGF (FGF-1) and bFGF (FGF-2), lack classical signal sequences, and the mechanism by which they are secreted is not known. Current data indicate that FGF-1 and FGF-2 are released from cells by a route that is distinct from the ER-Golgi secretory pathway (Florkiewicz, *et al.*, *J. Cell Physiol.* 162:388-399, 1995; Jackson, *et al.*, *J. Biol.*
20 *Chem.* 270:33-36, 1995).

The nine published members of the FGF family, FGFs 1-9, are between 155 and 268 amino acids in length and share approximately 25% or more amino acid sequence identity, as well as a conserved central region of approximately 140 amino acids. This region forms a compact beta-barrel with three-fold symmetry that is nearly identical in structure to the
25 folded core of interleukins 1-alpha and 1-beta (Zhu, *et al.*, *Science* 251:90-93, 1991; Zhang, *et al.*, *Proc. Natl. Acad. Sci. USA* 88:3446-3450, 1991; Eriksson, *et al.*, *Proc. Natl. Acad. Sci.*

USA 88:3441-3445, 1991; Ago, *et al.*, *J. Biochem.* 110:360-363, 1991). FGF-1 and FGF-2 also resemble interleukin 1-beta in lacking a classical signal sequence.

FGF signaling is generally thought to occur by activation of transmembrane tyrosine kinase receptors. For example, FGF-1, FGF-2, and FGF-7/KGF have been shown to exert some or all of their biological activities through high affinity binding to such receptors (see, *e.g.*, Lee, *et al.*, *Science*, 245:57, 1989; reviewed in Johnson and Williams, *Adv. Cancer Res.*, 60:1, 1993). Four FGF receptor (FGFR) genes have been identified thus far (Johnson, *et al.*, *Adv. Cancer Res.* 60:1-41, 1993), and activating or inactivating receptor mutations have been described for a subset of these genes, in both mice and humans. In the mouse, disruption of the FGFR1 or FGFR2 genes leads to early embryonic lethality (Deng, *et al.*, *Genes Dev.* 8:3045-3057, 1994; Yamaguchi, *et al.*, *Genes Dev.* 8:3032-3044, 1994), and disruption of FGFR3 leads to bone overgrowth (Deng, *et al.*, *Cell* 84:911-921, 1996; Colvin, *et al.*, *Nature Genet.* 12:390-397, 1996). In humans, point mutations in FGFR1, FGFR2, and FGFR3 have been found in a variety of skeletal disorders (reviewed by Muenke and Schell, *Trends Genet.* 11, 308-313, 1995). Recent work has shown that receptor diversity is increased by alternative pre-mRNA splicing within the extracellular ligand binding domain, with the result that multiple receptor isoforms, with different ligand binding properties, can be encoded by the same gene (Johnson and Williams, *supra*). In tissue culture systems, binding of aFGF or bFGF to its cell surface receptor activates phospholipase C-gamma (Burgess, *et al.*, *Mol. Cell Biol.*, 10:4770, 1990), which is a component of a pathway known to integrate a variety of mitogenic signals. Many members of the FGF family also bind tightly to heparin, and a ternary complex of heparin, FGF, and a transmembrane receptor may be a biologically relevant signaling species.

SUMMARY OF THE INVENTION

The invention provides fibroblast growth factor homologous factor (FHF) polypeptides and nucleic acids that encode them. FHFs are involved in regulating the growth, survival, and differentiation of cells in the central nervous system (CNS), as well as cells in peripheral nervous tissues.

5

The invention also provides methods for detecting alterations in FHF gene expression, which can be used in the diagnosis of neurodegenerative and neoplastic disorders. Methods for treating neurodegenerative and neoplastic disorders, in which the expression and/or activity of an FHF is modulated, are also included in the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows an alignment of the amino acid sequences of FHF-1 (SEQ ID NO:1), FHF-2 (SEQ ID NO:2), FHF-3 (SEQ ID NO:3), and FHF-4 (SEQ ID NO:4). Amino acids that are conserved in all four of FHF-1-4 are shaded and boxed and amino acids that are conserved in only some of FHF-1-4 are shaded.

Figure 2 shows an alignment of the amino acid sequences of FHF-1 (SEQ ID NO:1), FHF-2 (SEQ ID NO:2), FHF-3 (SEQ ID NO:3), FHF-4 (SEQ ID NO:4), FGF-1 (SEQ ID NO:5), FGF-2 (SEQ ID NO:6), and FGF-9 (SEQ ID NO:7). The large, black dots indicate amino acids that are identical among FHF-1-4, but that are different in the nine previously characterized FGFs (FGFs 1-9). Intron locations for murine FHF-2 are indicated by arrowheads above the aligned sequences. The locations of the twelve segments having beta-sheet conformations in the FGF-2 crystal structure are underlined (Erickson, *et al.*, *Proc. Natl. Acad. Sci. USA* 88:3441-3445, 1991).

Figure 3 shows an alignment of the amino acid sequences of mouse and human FHF-1 with each of the nine, previously characterized members of the FGF family (hFHF-1 (SEQ ID NO:1), hFHF-2 (SEQ ID NO:2), hFHF-3 (SEQ ID NO:3), hFHF-4 (SEQ ID NO:4), mFHF-1 (SEQ ID NO:8), mFHF-2 (SEQ ID NO:9), mFHF-3 (SEQ ID NO:10), and mFHF-4 (SEQ ID NO:11)).

The FGF family members include aFGF/FGF-1 (SEQ ID NO:5; Jaye, *et al.*, *supra*), bFGF/FGF-2 (SEQ ID NO:6; Abraham, *et al.*, *supra*), int-2/FGF-3 (SEQ ID NO:12; Smith, *et al.*, *supra*), FGF-4 (SEQ ID NO:13; Delli-Bovi, *et al.*, *supra*), FGF-5 (SEQ ID NO:14; Zhan, *et al.*, *supra*), FGF-6 (SEQ ID NO:15; Maricas, *et al.*, *supra*), keratinocyte growth factor/FGF-7 (SEQ ID NO:16; Finch, *et al.*, *supra*), FGF-8 (SEQ ID NO:17;

Tanaka, *et al.*, *supra*), and FGF-9 (SEQ ID NO:7; Miyamoto, *et al.*, *supra*). (“m” denotes mouse, and “h” denotes human.)

Figure 4 shows a dendrogram of mammalian FHF and FGF family members, in which the length of each path connecting any pair of FHF or FGF family members is proportional to the degree of amino acid sequence divergence of that pair. (“m” denotes mouse, and “h” denotes human.)

Figure 5 shows the nucleotide (SEQ ID NO:18) and deduced amino acid (SEQ ID NO:1) sequences of FHF-1.

Figure 6 shows the nucleotide (SEQ ID NO:19) and deduced amino acid (SEQ ID NO:2) sequences of FHF-2.

Figure 7 shows the nucleotide (SEQ ID NO:20) and deduced amino acid (SEQ ID NO:3) sequences of FHF-3.

Figure 8 shows the nucleotide (SEQ ID NO:21) and deduced amino acid (SEQ ID NO:4) sequences of FHF-4.

Figure 9 shows partial chromosome linkage maps for mouse FHF-1, FHF-2, and FHF-3 genes. The genes were mapped by interspecific backcross analysis. To the left of each chromosome map, the number of recombinant N2 animals is presented, divided by the total number of N2 animals typed for each pair of loci. The recombination frequencies, expressed as genetic distance in centimorgans (+/- one standard error) are also shown. The upper 95% confidence limit of the recombination distance is given in parentheses, in cases where no recombinants were found between loci. The positions of loci on human chromosomes,

where known, are shown to the right of the chromosome maps. References for the map positions of most human loci can be obtained from the GDB (Genome Data Base), which is a computerized database of human linkage information maintained by The William H. Welch Medical Library of The Johns Hopkins University (Baltimore, Maryland).

5 Figure 10 shows the tissue distribution of FHF transcripts in the adult mouse. Ten micrograms of total RNA from various mouse tissues was prepared (Chomczynski and Sacchi, *Anal. Biochem.*, 162:156, 1987) and used in RNase protection experiments (Ausubel, *et al.*, *Current Protocols in Molecular Biology*, Wiley Interscience, New York, New York, 1987) employing the indicated antisense riboprobes (FHF-1-4). The RNA
10 samples are as follows: 1, brain; 2, eye; 3, heart; 4, kidney; 5, liver; 6, lung; 7, spleen; 8, testis; and 9, yeast tRNA. A control reaction, in which an RNA Polymerase II probe was used, is shown at the bottom of the figure.

Figure 11 shows *in situ* localization of FHF transcripts in sections prepared from the developing and adult mouse. ³³P *in situ* hybridization is shown in red and is superimposed
15 on a cresyl violet stain shown in black and white. The probes and samples used are as follows: (A) FHF-2, e11; (B) FHF-3, e11; (C, D) FHF-2, e17; (E) FHF-1, P1, coronal section through the head at the level of the eyes; (F) FHF-2, P1, coronal section through the center of the head; (G) FHF-1, adult; (H, I) FHF-2, adult; (J) FHF-3, adult; (K, L) FHF-4, adult.

20 Figure 12 shows FHF-1 immunostaining in sections of the macaque monkey CNS. The samples stained are as follows: (A) precentral motor cortex; (B) area 3b in the primary somatosensory cortex; (C) primary auditory cortex; (D) area 7b in the superior parietal lobule; and (E) primary visual cortex. Panels F-H show that populations of cortical neurons immunoreactive for FHF-1 include large intensely, immunoreactive cells (arrows), small,

weakly immunoreactive cells (arrowheads), and small, weakly immunoreactive cells, with fine processes resembling microglia (double arrows). Simultaneous immunostaining for parvalbumin (G) and FHF-1 (H) shows that large and small neurons are immunoreactive for both. An uneven distribution of FHF-1 immunoreactive somata is seen in the hippocampal formation (I), including the subicular complex (S), the CA fields, and the dentate gyrus (DG). In the dorsal thalamus (J), FHF-1 immunoreactive somata occupy patches in the caudal ventroposteriolateral nucleus (VPLc) and are found in both magnocellular and parvocellular layers of the lateral geniculate nucleus (LGN). The medial geniculate complex contains few immunostained cells. In the basal telencephalon (K), immunoreactive neurons are present in both the external and internal segments of the globus pallidus (Gpe and GPi). Scale bars: 500 μ m in (A-E), 20 μ m in (F), 75 μ m in (G, H), and 1 mm in (I-K).

Figure 13 shows that FHF-1 is not secreted by 293 cells, which are human embryonic kidney cells. 293 cells were transiently transfected with plasmids directing expression of human growth hormone (left 2 lanes; hGH), FHF-1 (center 2 lanes), or the human red cone pigment (right 2 lanes; Red). The cells were labeled for 6 hours with 35 S-methionine in serum-free medium, and the total protein present in the cells (C) or medium (M) was resolved by SDS-PAGE and visualized by autoradiography. Secretion of hGH, but not FHF-1, is observed. The mobilities of protein standards are indicated at the left of the figure; from top to bottom, their molecular masses, in kDa, are: 220, 97, 66, 46, 30, 21.5, and 14.3. The mobilities of hGH and FHF-1 are indicated at the right side of the figure.

Figure 14 shows a summary of FHF-1 constructs used to identify the FHF-1 nuclear localization signal (NLS). Localization of these constructs by immunostaining (constructs 1-4) and localization of FHF-1- β -galactosidase fusions by X-gal staining (constructs 5-12) is also shown. The numbers underneath each construct indicate the amino acids from FHF-1 that are present in the construct. (N, nuclear staining; C, cytoplasmic

staining; ++, strong staining; +, weak staining; -, no staining. 'a', construct 12 shows cytoplasmic staining in 15%-20% of cells and nuclear localization in 80%-85% of cells.)

5 Figure 15 shows double label immunofluorescent localization of the constructs illustrated in Figure 14. The antibodies used are as follows: (A, B) double label immunofluorescent localization of FHF-1 (green) and BiP (an ER marker; red), optically sectioned at 0.7 μm ; and (C-F) histochemical localization of FHF-1- β -galactosidase fusion proteins. All experiments were performed in transiently transfected 293 cells. The constructs used are: (A) full length FHF-1, construct 1; (B) construct 4; (C) full length β -galactosidase; (D) construct 6; (E) construct 11; (F) construct 12.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides polypeptide growth factors, designated fibroblast growth factor homologous factors (FHF), and nucleic acids that encode them. Genes encoding four FHF, designated FHF-1-4, have been isolated and sequenced. The deduced amino acid sequence of FHF-1 is 27% identical to that of FGF-9, and the amino acid sequences of FHF-1-4 are 58-70% identical to each other. Thus, FHF define a new branch of the FGF family.

FHF are expressed in the developing and adult nervous systems, and thus are believed to play roles in regulating nervous system development and function. Accordingly, FHF polypeptides, and nucleic acids that encode them, can be used in methods for treating and diagnosing conditions affecting the nervous system, including, *e.g.*, stroke, neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, retinal degenerative diseases, such as retinitis pigmentosa and macular degeneration, cerebellar degenerative diseases, and cancer. More specific uses for FHF-related molecules can be gleaned from their tissue specificities. For example, although FHF-1-4 are all expressed in the brain, FHF-1-3 are specifically expressed in the eye, FHF-1 and 4 are expressed in the testes, and FHF-2 is expressed in the heart. Thus, monoclonal and polyclonal antibodies can be produced using standard immunization and screening methods well known in the art. These antibodies can be easily detectably labelled and used histologically to identify tissues which contain a given FHF. FHF can also be used in methods for maintaining cultured cells or tissues, such as neuronal cells or tissues, prior to transplantation. In addition, FHF can be used to promote neuron growth *in vitro*, in order to, for example, facilitate production of growth factors, such as interleukin-2 (IL-2), that are produced by them. Methods employing FHF polypeptides and nucleic acids are described in further detail below.

The invention provides substantially pure FHF polypeptides. FHF polypeptides can be characterized as containing, for example, at least five consecutive amino acids that are conserved in at least two, *e.g.*, three or four, FHF, such as FHF, 1-4. One or more (*e.g.*, two to four) of the five conserved amino acids, in addition to being conserved in FHF, can be characterized as not being conserved in any of the nine previously characterized FGFs (FGFs 1-9, see above).

The term "substantially pure" is used herein to describe a molecule, such as a polypeptide (*e.g.*, an FHF polypeptide, or a fragment thereof) that is substantially free of other proteins, lipids, carbohydrates, nucleic acids, and other biological materials with which it is naturally associated. For example, a substantially pure molecule, such as a polypeptide, can be at least 60%, by dry weight, the molecule of interest. One skilled in the art can purify FHF polypeptides using standard protein purification methods and the purity of the polypeptides can be determined using standard methods including, *e.g.*, polyacrylamide gel electrophoresis (*e.g.*, SDS-PAGE), column chromatography (*e.g.*, high performance liquid chromatography (HPLC)), and amino-terminal amino acid sequence analysis.

FHF polypeptides included in the invention can have one of the amino acid sequences of FHF, 1-4, for example, the amino acid sequence of FHF-4. FHF polypeptides, such as FHF, 1-4, can be characterized by being expressed in the brain, lacking classical signal sequences, containing nuclear localization signals or nuclear localization-like signals, and containing, at full length, about 225-250 amino acids (FHF-1: 244 amino acids; FHF-2: 245 amino acids; FHF-3: 225 amino acids; FHF-4: 247 amino acids; see, *e.g.*, Figures 1-3 and 5-8). The FHF polypeptides of the invention can be derived from a mammal, such as a human or a mouse.

Also included in the invention are polypeptides having sequences that are "substantially identical" to the sequence of an FHF polypeptide, such as one of FHFs 1-4, *e.g.*, FHF-4. A "substantially identical" amino acid sequence is a sequence that differs from a reference sequence only by conservative amino acid substitutions, for example, substitutions of one amino acid for another of the same class (*e.g.*, substitution of one hydrophobic amino acid, such as isoleucine, valine, leucine, or methionine, for another, or substitution of one polar amino acid for another, such as substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine), or by one or more non-conservative substitutions, deletions, or insertions, provided that the polypeptide retains at least one FHF-specific activity or an FHF-specific epitope. For example, one or more amino acids can be deleted from an FHF polypeptide, resulting in modification of the structure of the polypeptide, without significantly altering its biological activity. For example, amino- or carboxyl-terminal amino acids that are not required for FHF biological activity, can be removed. Such modifications can result in the development of smaller active FHF polypeptides.

Other FHF polypeptides included in the invention are polypeptides having amino acid sequences that are at least 50% identical to the amino acid sequence of an FHF polypeptide, such as any of FHFs 1-4, *e.g.*, FHF-4. The length of comparison in determining amino acid sequence homology can be, for example, at least 15 amino acids, for example, at least 20, 25, or 35 amino acids. Homology can be measured using standard sequence analysis software (*e.g.*, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705; also see Ausubel, *et al.*, *supra*).

The invention also includes fragments of FHF polypeptides, such as FHFs 1-4, that retain at least one FHF-specific activity or epitope. For example, an FHF polypeptide fragment containing, *e.g.*, at least 8-10 amino acids can be used as an immunogen in the production

of FHF-specific antibodies. The fragment can contain, for example, an amino acid sequence that is conserved in FHF, and this amino acid sequence can contain amino acids that are conserved in FHF, but not in FGFs 1-9. Such fragments can easily be identified by comparing the sequences of FHF and FGFs, *e.g.*, by reference to Figures 1-3. In addition to their use as peptide immunogens, the above-described FHF fragments can be used in immunoassays, such as ELISAs, to detect the presence of FHF-specific antibodies in samples.

The FHF polypeptides of the invention can be obtained using any of several standard methods. For example, FHF polypeptides can be produced in a standard recombinant expression systems (see below), chemically synthesized (this approach may be limited to small FHF peptide fragments), or purified from tissues in which they are naturally expressed (see, *e.g.*, Ausubel, *et al.*, *supra*).

The invention also provides isolated nucleic acid molecules that encode the FHF polypeptides described above, as well as fragments thereof. For example, nucleic acids that encode any of FHF 1-4, such as FHF-4, are included in the invention. These nucleic acids can contain naturally occurring nucleotide sequences (see Figures 1-3 and 5-8), or sequences that differ from those of the naturally occurring nucleic acids that encode FHF 1-4, but encode the same amino acids, due to the degeneracy of the genetic code. The nucleic acids of the invention can contain DNA or RNA nucleotides, or combinations or modifications thereof.

By "isolated nucleic acid" is meant a nucleic acid, *e.g.*, a DNA or RNA molecule, that is not immediately contiguous with the 5' and 3' flanking sequences with which it normally is immediately contiguous when present in the naturally occurring genome of the organism from which it is derived. The term thus describes, for example, a nucleic acid that is

incorporated into a vector, such as a plasmid or viral vector; a nucleic acid that is incorporated into the genome of a heterologous cell (or the genome of a homologous cell, but at a site different from that at which it naturally occurs); and a nucleic acid that exists as a separate molecule, *e.g.*, a DNA fragment produced by PCR amplification or restriction enzyme digestion, or an RNA molecule produced by *in vitro* transcription. The term also describes a recombinant nucleic acid that forms part of a hybrid gene encoding additional polypeptide sequences that can be used, for example, in the production of a fusion protein.

The nucleic acid molecules of the invention can be used as templates in standard methods for production of FHF gene products (*e.g.*, FHF RNAs and FHF polypeptides; see below).

In addition, the nucleic acid molecules that encode FHF polypeptides (and fragments thereof) and related nucleic acids, such as (1) nucleic acids containing sequences that are complementary to, or that hybridize to, nucleic acids encoding FHF polypeptides, or fragments thereof (*e.g.*, fragments containing at least 12, 15, 20, or 25 nucleotides); and (2) nucleic acids containing sequences that hybridize to sequences that are complementary to nucleic acids encoding FHF polypeptides, or fragments thereof (*e.g.*, fragments containing at least 12, 15, 20, or 25 nucleotides); can be used in methods focused on their hybridization properties. For example, as is described in further detail below, such nucleic acid molecules can be used in the following methods: PCR methods for synthesizing FHF nucleic acids, methods for detecting the presence of an FHF nucleic acid in a sample, screening methods for identifying nucleic acids encoding new FHF family members, and therapeutic methods.

The invention also includes methods for identifying nucleic acid molecules that encode members of the FHF polypeptide family in addition to FHF 1-4. In these methods, a sample, *e.g.*, a nucleic acid library, such as a cDNA library, that contains a nucleic acid encoding an FHF polypeptide is screened with an FHF-specific probe, *e.g.*, an FHF-specific nucleic acid probe. FHF-specific nucleic acid probes are nucleic acid molecules (*e.g.*,

molecules containing DNA or RNA nucleotides, or combinations or modifications thereof that specifically hybridize to nucleic acids encoding FHF polypeptides, or to complementary sequences thereof. Because FHF are closely related to FGFs (*i.e.*, the first nine members of the FGF family (FGFs 1-9), see above), the term "FHF-specific probe," in the context of this method of invention, refers to probes that bind to nucleic acids encoding FHF polypeptides, or to complementary sequences thereof, to a detectably greater extent than to nucleic acids encoding FGFs, or to complementary sequences thereof. The term "FHF-specific probe" thus includes probes that can bind to nucleic acids encoding FHF polypeptides (or to complementary sequences thereof), but not to nucleic acids encoding FGFs (or to complementary sequences thereof), to an appreciable extent.

The invention facilitates production of FHF-specific nucleic acid probes. Methods for obtaining such probes can be designed based on the amino acid sequence alignments shown in Figures 1-3. In Figure 1, for example, amino acid sequences that are conserved in FHF ("FHF-conserved amino acids") are boxed. In Figure 2, amino acids that are conserved in FHF, but not in FGFs (*i.e.*, FGFs 1-9) ("FHF-specific amino acids"), are indicated by large, black dots. The probes, which can contain at least 12, *e.g.*, at least 15, 25, 35, 50, 100, or 150 nucleotides, can be produced using any of several standard methods (see, *e.g.*, Ausubel, *et al.*, *supra*). For example, preferably, the probes are generated using PCR amplification methods, such as those described below in Example 1. In these methods, primers are designed that correspond to FHF-conserved sequences (Figure 1), which can include FHF-specific amino acids, and the resulting PCR product is used as a probe to screen a nucleic acid library, such as a cDNA library. A nucleotide sequence encoding FHF-4 was identified generally following this process based upon the analysis of the sequences of FHF 1-3.

As is known in the art, PCR primers are typically designed to contain at least 15 nucleotides, for example 15-30 nucleotides. The design of FHF-specific primers containing 21

nucleotides, which encode FHF peptides containing 7 amino acids, are described as follows. Preferably, most or all of the nucleotides in such a probe encode FHF-conserved amino acids, including FHF-specific amino acids. For example, primers containing sequences encoding peptides containing at least 40% FHF-conserved amino acids can be used. Such
5 a primer, containing 21 nucleotides, can include sequences encoding at least 3/7, 4/7, 5/7, 6/7, or 7/7 FHF-conserved amino acids. As can be determined by analysis of Figures 1-3, in the case of a 21 nucleotide primer, encoding 7 amino acids, up to 5 amino acids can be FHF-specific. Thus, the primer can contain sequences encoding at least one FHF-specific amino acid, for example, up to 5 FHF-specific amino acids. Once FHF-specific amino acid
10 sequences are selected as templates against which primer sequences are to be designed, the primers can be synthesized using, *e.g.*, standard chemical methods. As is described above, due to the degeneracy of the genetic code, such primers should be designed to include appropriate degenerate sequences, as can readily be determined by one skilled in the art (see above, and Example 1, below).

15 Based on the guidelines presented above, examples of FHF-conserved amino acid peptides that can be used as templates for the design of FHF-specific primers are as follows. Additional examples can be found by analysis of sequence alignments of FHF polypeptides, for example, the alignments in Figures 1-3. Primers can be designed, for example, based on 5-10 amino acid regions of these peptides, depending on the lengths of the primers desired.
20 For example, primers can be designed to correspond to 7 consecutive amino acids of any of the segments shown below.

1. A A A I/L A S S/G S L I R Q K R (SEQ ID NO:22)
(corresponding to amino acids 2-14 of human FHF-1)
2. P Q L K G I V T R/K (SEQ ID NO:23)
25 (corresponding to amino acids 68-76 of human FHF-1)

3. T L/H F N L I P V G L R V V (SEQ ID NO:24)
(corresponding to amino acids 104-116 of human FHF-1)
4. A M N G/S/A E G Y/L L Y (SEQ ID NO:25)
(corresponding to amino acids 128-136 of human FHF-1)
- 5 5. K E S/C V F E N Y Y V (SEQ ID NO:26)
(corresponding to amino acids 148-157 of human FHF-1; see Example 1, below, for an example of a primer based on the "V F E N Y Y V" (SEQ ID NO:27) portion of this sequence.)
- 10 6. S G R A/G W F/Y L G L (SEQ ID NO:28)
(corresponding to amino acids 169-177 of human FHF-1)
7. M K G N R/H V K K T/N K (SEQ ID NO:29)
(corresponding to amino acids 184-193 of human FHF-1; see Example 1, below, for an example of a primer based on the "M K G N H/R V K" (SEQ ID NO:30) portion of this sequence.)
- 15 8. V C/A M Y R/Q/K E P S L H (SEQ ID NO:31)
(corresponding to amino acids 205-214 of human FHF-1)

As is described above, FHF-specific primers, for example primers based on the FHF-specific peptides shown above, or portions thereof, can be used in PCR reactions to generate FHF-specific probes, which can be used in standard screening methods to identify nucleic acids encoding FHF family members (see, *e.g.*, Ausubel, *et al.*, *supra*).

In addition to FHF-specific nucleic acid probes, FHF-specific polypeptide probes, such as FHF-specific antibodies, can be used to screen samples, *e.g.*, expression libraries, for nucleic acids encoding novel FHF polypeptides, or portions thereof. For example, an antibody that specifically binds to an FHF-specific peptide can be used in this method. Methods for carrying out such screening are well known in the art (see, *e.g.*, Ausubel, *et al.*, *supra*).

The sequences of a pair of nucleic acid molecules (or two regions within a single nucleic acid molecule) are said to be "complementary" to each other if base pairing interactions can occur between each nucleotide of one of the members of the pair and each nucleotide of the other member of the pair. A pair of nucleic acid molecules (or two regions within a single nucleic acid molecule) are said to "hybridize" to each other if they form a duplex by base pairing interactions between them. As is known in the art, hybridization between nucleic acid pairs does not require complete complementarity between the hybridizing regions, but only that there is a sufficient level of base pairing to maintain the duplex under the hybridization conditions used.

Hybridization reactions are typically carried out under low to moderate stringency conditions, in which specific and some non-specific interactions can occur. After hybridization, washing can be carried out under moderate or high stringency conditions to eliminate non-specific binding. As is known in the art, optimal washing conditions can be determined empirically, *e.g.*, by gradually increasing the stringency. Condition parameters that can be changed to affect stringency include, *e.g.*, temperature and salt concentration. In general, the lower the salt concentration and the higher the temperature, the higher the stringency. For example, washing can be initiated at a low temperature (*e.g.*, room temperature) using a solution containing an equivalent or lower salt concentration as the hybridization solution. Subsequent washing can be carried out using progressively warmer solutions having the same salt solution. Alternatively, the salt concentration can be lowered and the temperature maintained in the washing step, or the salt concentration can be lowered and the temperature increased. Additional parameters can be altered to affect stringency, including, *e.g.*, the use of a destabilizing agent, such as formamide.

In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For

example, the length, degree of complementarity, nucleotide sequence composition (*e.g.*, GC v. AT content), and nucleic acid type (*e.g.*, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

5 An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). Washing can be carried out using only one of these conditions, *e.g.*, high stringency conditions, or
10 each of the conditions can be used, *e.g.*, for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.

15 The nucleic acid molecules of the invention can be obtained by any of several standard methods. For example, the molecules can be produced using standard recombinant, enzymatic (*e.g.*, PCR or reverse transcription (RT)/PCR methods), and chemical (*e.g.*, phosphoramidite-based synthesis) methods. In addition, they can be isolated from samples, such as nucleic acid libraries and tissue samples, using standard hybridization
20 methods. For example, as described above, using standard methods, genomic or cDNA libraries can be hybridized with nucleic acid probes corresponding to FHF nucleic acid sequences to detect the presence of a homologous nucleotide sequence in the library (see, *e.g.*, Ausubel, *et al.*, *supra*). These methods are described in more detail above. Also as described above, nucleic acids encoding polypeptides containing at least one FHF epitope,
25 such as an FHF-specific epitope, can also be identified by screening a cDNA expression library, such as a library contained in lambda gt11, with an FHF-specific antibody as a probe. Such antibodies can be either polyclonal or monoclonal and are produced using standard

methods (see, *e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988).

The FHF nucleic acid molecules can be inserted into vectors, such as plasmid or viral vectors, that facilitate (1) expression of the inserted nucleic acid molecule and/or (2) amplification of the insert. As is well known in the art, such vectors can contain, *e.g.*, promoter sequences, which facilitate transcription of the inserted nucleic acid in the cell, origins of replication, and genes, such as a neomycin-resistance gene, which encodes a selectable marker that imparts G418 resistance to cells in which it is expressed, and thus permits phenotypic selection of transformed cells.

Vectors suitable for use in the present invention include, *e.g.*, T7-based expression vectors for use in bacteria (see, *e.g.*, Rosenberg, *et al.*, *Gene*, 56:125, 1987), the pMSXND expression vector for use in mammalian cells (Lee and Nathans, *J. Biol. Chem.*, 263:3521, 1988), and baculovirus-derived vectors for use in insect cells. The nucleic acids in such vectors are operably linked to a promoter, which is selected based on, *e.g.*, the cell type in which expression is sought. For example, a T7 promoter can be used in bacteria, a polyhedrin promoter can be used in insect cells, and a cytomegalovirus or metallothionein promoter can be used in mammalian cells. Also, in the case of higher eukaryotes, tissue-specific promoters are available. (See, *e.g.*, Ausubel, *et al.*, *supra*, for additional appropriate vectors and promoters that can be used in the invention; also see Pouwels, *et al.*, *Cloning Vectors: A Laboratory Manual*, 1985, Supp. 1987). Viral vectors that can be used in the invention include, for example, retroviral, adenoviral, adeno-associated viral, herpes virus, simian virus 40 (SV40), and bovine papilloma virus vectors (see, *e.g.*, Gluzman ed., *Eukaryotic Viral Vectors*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1982), and are discussed further below.

Cells into which FHF nucleic acids can be introduced, in order to, for example, produce FHF polypeptides using, *e.g.*, the vectors described above, include prokaryotic cells (*e.g.*, bacterial cells, such as *E. coli* cells) and eukaryotic cells (*e.g.*, yeast cells, such as *Saccharomyces cerevisiae* cells; insect cells, such as *Spodoptera frugiperda* cells (*e.g.*, Sf-9 cells); and mammalian cells, such as CHO, Cos-1, NIH-3T3, and JEG3 cells). Such cells are available from a number of different sources that are known to those skilled in the art, *e.g.*, the American Type Culture Collection (ATCC), Rockville, Maryland (also see Ausubel, *et al.*, *supra*). Cells into which the nucleic acids of the invention have been introduced, as well as their progeny, even if not identical to the parental cells, due to mutations, are included in the invention.

Methods for introducing the nucleic acids of the invention (*e.g.*, nucleic acids inserted into the vectors described above) into cells, either transiently or stably, are well known in the art (see, *e.g.*, Ausubel, *et al.*, *supra*). For example, in the case of prokaryotic cells, such as *E. coli* cells, competent cells, which are prepared from exponentially growing bacteria using a standard CaCl_2 (or MgCl_2 or RbCl) method, can be transformed using standard methods. Transformation of bacterial cells can also be performed using protoplast fusion methods. In the case of eukaryotic cells, transfection can be carried out using calcium phosphate precipitation or conventional mechanical procedures, such as microinjection and electroporation, can be used. Also, the nucleic acid (*e.g.*, contained in a plasmid) can be packaged in a liposome using standard methods. In the case of viral vectors, appropriate infection methods, which are well known in the art, can be used (see, *e.g.*, Ausubel, *et al.*, *supra*). In addition to being transfected with a nucleic acid encoding an FHF polypeptide of the invention, eukaryotic cells, such as mammalian cells, can be co-transfected with a second nucleic acid encoding a selectable marker, such as a neomycin resistance gene or the herpes simplex virus thymidine kinase gene. As is mentioned above, such selectable markers can facilitate selection of transformed cells.

Isolation and purification of polypeptides produced in the systems described above can be carried out using conventional methods, appropriate for the particular system. For example, preparative chromatography and immunological separations employing antibodies, such as monoclonal or polyclonal antibodies, can be used.

5 Antibodies, such as monoclonal and polyclonal antibodies, that specifically bind to FHF polypeptides (*e.g.*, any or all of FHF 1-4) are also included in the invention. These antibodies can be made by using an FHF polypeptide, or an FHF polypeptide fragment that maintain an FHF epitope, as an immunogen in standard antibody production methods (see, *e.g.*, Kohler, *et al.*, *Nature*, 256:495, 1975; Ausubel, *et al.*, *supra*; Harlow and Lane, *supra*).

10 The term "antibody," as used herein, refers to intact immunoglobulin molecules, as well as fragments of immunoglobulin molecules, such as Fab, Fab', (Fab')₂, Fv, and SCA fragments, that are capable of binding to an epitope of an FHF polypeptide. These antibody fragments, which retain some ability to selectively bind to the antigen (*e.g.*, an FHF antigen) of the antibody from which they are derived, can be made using well known methods in the art (see,
15 *e.g.*, Harlow and Lane, *supra*), and are described further, as follows.

(1) A Fab fragment consists of a monovalent antigen-binding fragment of an antibody molecule, and can be produced by digestion of a whole antibody molecule with the enzyme papain, to yield a fragment consisting of an intact light chain and a portion of a heavy chain.

(2) A Fab' fragment of an antibody molecule can be obtained by treating a whole antibody
20 molecule with pepsin, followed by reduction, to yield a molecule consisting of an intact light chain and a portion of a heavy chain. Two Fab' fragments are obtained per antibody molecule treated in this manner.

(3) A (Fab')₂ fragment of an antibody can be obtained by treating a whole antibody molecule with the enzyme pepsin, without subsequent reduction. A (Fab')₂ fragment is a dimer of two Fab' fragments, held together by two disulfide bonds.

5 (4) An Fv fragment is defined as a genetically engineered fragment containing the variable region of a light chain and the variable region of a heavy chain expressed as two chains.

(5) A single chain antibody ("SCA") is a genetically engineered single chain molecule containing the variable region of a light chain and the variable region of a heavy chain, linked by a suitable, flexible polypeptide linker.

10 As used in this invention, the term "epitope" refers to an antigenic determinant on an antigen, such as an FHF polypeptide, to which the paratope of an antibody, such as an FHF-4-specific antibody, binds. Antigenic determinants usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three-dimensional structural characteristics, as well as specific charge characteristics.

15 As is mentioned above, antigens that can be used in producing FHF-specific antibodies include FHF polypeptides, *e.g.*, any of FHF 1-4, or FHF polypeptide fragments. The polypeptide or peptide used to immunize an animal can be obtained by standard recombinant, chemical synthetic, or purification methods. As is well known in the art, in order to increase immunogenicity, an antigen can be conjugated to a carrier protein. Commonly used carriers include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine
20 serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize the animal (*e.g.*, a mouse, a rat, or a rabbit). In addition to such carriers, well known adjuvants can be administered with the antigen to facilitate induction of a strong immune response.

FHF-specific polyclonal and monoclonal antibodies can be purified, for example, by binding to, and elution from, a matrix containing an FHF polypeptide, *e.g.*, the FHF polypeptide (or fragment thereof) to which the antibodies were raised. Additional methods for antibody purification and concentration are well known in the art and can be practiced with the FHF-specific antibodies of the invention (see, for example, Coligan, *et al.*, Unit 9, *Current Protocols in Immunology*, Wiley Interscience, 1994).

Anti-idiotypic antibodies corresponding to FHF-specific antigens are also included in the invention, and can be produced using standard methods. These antibodies are raised to FHF-specific antibodies, and thus mimic FHF-specific epitopes.

The members of a pair of molecules (*e.g.*, an antibody-antigen pair or a nucleic acid pair) are said to "specifically bind" to each other if they bind to each other with greater affinity than to other, non-specific molecules. For example, an antibody raised against an antigen to which it binds more efficiently than to a non-specific protein can be described as specifically binding to the antigen. (Similarly, a nucleic acid probe can be described as specifically binding to a nucleic acid target if it forms a specific duplex with the target by base pairing interactions (see above).)

As is discussed above, because of their amino acid sequence homologies to previously identified FGF polypeptides (*i.e.*, FGFs 1-9), as well as their tissue localizations, FGFs are thought to play roles in regulating the development and function of the nervous system. Altered levels of FGFs, such as increased levels, may thus be associated with cell proliferative disorders, such as cell proliferative disorders of the nervous system. The term "cell-proliferative disorder" is used herein to describe conditions that are characterized by abnormally excessive cell growth, including malignant, as well as non-malignant, cell growth. Conversely, conditions characterized by inadequate cell growth may be

characterized by decreased expression of FHF's. Accordingly, these conditions can be diagnosed and monitored by detecting the levels of FHF's in patient samples.

5 FHF-specific antibodies and nucleic acids can be used as probes in methods to detect the presence of an FHF polypeptide (using an antibody) or nucleic acid (using a nucleic acid probe) in a sample, such as a biological fluid (*e.g.*, cerebrospinal fluid (CSF), such as lumbar or ventricular CSF) or a tissue sample (*e.g.*, CNS tissue, *e.g.*, neural tissue or eye tissue). In these methods, an FHF-specific antibody or nucleic acid probe is contacted with a sample from a patient suspected of having an FHF-associated disorder, and specific binding of the antibody or nucleic acid probe to the sample detected. The level of FHF polypeptide or
10 nucleic acid present in the suspect sample can be compared with the level in a control sample, *e.g.*, an equivalent sample from an unaffected individual, to determine whether the patient has an FHF-associated cell proliferative disorder. FHF polypeptides, or fragments thereof, can also be used as probes in diagnostic methods, for example, to detect the presence of FHF-specific antibodies in samples.

15 The FHF-specific nucleic acid probes can be labeled with a compound that facilitates detection of binding to the FHF nucleic acid in the sample. For example, the probe can contain biotinylated nucleotides, to which detectably labeled avidin conjugates (*e.g.*, horseradish peroxidase-conjugated avidin) can bind. Radiolabeled nucleic acid probes can also be used. These probes can be used in nucleic acid hybridization assays to detect altered
20 levels of FHF's in a sample. For example, *in situ* hybridization, RNase protection, and Northern Blot methods can be used. Other standard nucleic acid detection methods that can be used in the invention are known to those of skill in the art (see, *e.g.*, Ausubel, *et al.*, *supra*). In addition, when the diagnostic molecule is a nucleic acid, it can be amplified prior to binding with an FHF-specific probe. Preferably, PCR is used, but other nucleic acid
25 amplification methods, such as the ligase chain reaction (LCR), ligated activated

transcription (LAT), and nucleic acid sequence-based amplification (NASBA) methods can be used.

5 Use of FHF-specific antibodies in diagnostic methods is described further, as follows. The antibodies of the invention can be used *in vitro* or *in vivo* for immunodiagnosis. The antibodies are suited for use in, for example, immunoassays in which they are in liquid phase or bound to a solid phase carrier (*e.g.*, a glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylose, natural and modified cellulose, polyacrylamide, agarose, or magnetite carrier). The antibodies used in such immunoassays can be detectably labeled (*e.g.*, with an enzyme, a radioisotope, a fluorescent compound, a colloidal metal, a chemi-
10 luminescent compound, a phosphorescent compound, or a bioluminescent compound) using any of several standard methods that are well known in the art. Examples of immunoassays in which the antibodies of the invention can be used include, *e.g.*, competitive and non-competitive immunoassays, which are carried out using either direct or indirect formats. Examples of such immunoassays include radioimmunoassays (RIA) and sandwich assays
15 (*e.g.*, enzyme-linked immunosorbent assays (ELISAs)). Detection of antigens using the antibodies of the invention can be done using immunoassays that are run in either forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Other immunoassay formats are well known in the art, and can be used in the invention (see, *e.g.*, Coligan, *et al.*, *supra*).

20 In addition to the *in vitro* methods described above, FHF-specific monoclonal antibodies can be used in methods for *in vivo* detection of an antigen, such as an FHF antigen (*e.g.*, any one of FHF1-4). In these methods, a detectably labeled antibody is administered to a patient in a dose that is determined to be diagnostically effective by one skilled in the art. The term "diagnostically effective" is used herein to describe the amount of detectably labeled
25 monoclonal antibody that is administered in a sufficient quantity to enable detection of the

site having the antigen for which the monoclonal antibody is specific. As would be apparent to one skilled in the art, the concentration of detectably labeled monoclonal antibody that is administered should be sufficient so that the binding of the antibody to the cells containing the polypeptide is detectable, compared to background. Further, it is desirable that the detectably labeled monoclonal antibody is rapidly cleared from the circulatory system, to give the optimal target-to-background signal ratio.

The dosage of detectably labeled monoclonal antibodies for *in vivo* diagnosis will vary, depending on such factors as the age and weight of the individual, as well as the extent of the disease. The dosages can also vary depending on factors such as whether multiple administrations are intended, antigenic burden, and other factors known to those of skill in the art.

In addition to initial diagnosis, the FHF polypeptides, nucleic acids, and FHF-specific antibodies described above can be used in *in vitro* or *in vivo* methods for monitoring the progress of a condition associated with FHF expression. For example, they can be used in methods to monitor the course of amelioration of an FHF-associated disease, for example, after treatment has begun. In these methods, changes in the levels of an FHF-specific marker (*e.g.*, an FHF polypeptide, an FHF nucleic acid, or an FHF-specific antibody) are detected, either in a sample from a patient or using the *in vivo* methods described above.

The invention also provides methods for treating conditions associated with altered expression of FHF polypeptides, for example, cell proliferative disorders (*e.g.*, cell proliferative disorders of the central or peripheral nervous systems, for example, conditions affecting neural tissue, testes, heart tissue, and cells of the eye). Treatment of an FHF-associated cell proliferative disorder can be carried out, for example, by modulating FHF gene expression or FHF activity in a cell. The term "modulate" includes, for example,

suppressing expression of an FHF when it is over-expressed, and augmenting expression of an FHF when it is under-expressed. In cases where a cell-proliferative disorder is associated with over-expression of an FHF, nucleic acids that interfere with FHF expression, at transcriptional or translational levels, can be used to treat the disorder. This approach employs, for example, antisense nucleic acids (*i.e.*, nucleic acids that are complementary to, or capable of hybridizing with, a target nucleic acid, *e.g.*, a nucleic acid encoding an FHF polypeptide), ribozymes, or triplex agents. The antisense and triplex approaches function by masking the nucleic acid, while the ribozyme strategy functions by cleaving the nucleic acid. In addition, antibodies that bind to FHF polypeptides can be used in methods to block the activity of an FHF.

The use of antisense methods to inhibit the *in vitro* translation of genes is well known in the art (see, *e.g.*, Marcus-Sakura, *Anal. Biochem.*, 172:289, 1988). Antisense nucleic acids are nucleic acid molecules (*e.g.*, molecules containing DNA nucleotides, RNA nucleotides, or modifications (*e.g.*, modification that increase the stability of the molecule, such as 2'-O-alkyl (*e.g.*, methyl) substituted nucleotides) or combinations thereof) that are complementary to, or that hybridize to, at least a portion of a specific nucleic acid molecule, such as an RNA molecule (*e.g.*, an mRNA molecule) (see, *e.g.*, Weintraub, *Scientific American*, 262:40, 1990). The antisense nucleic acids hybridize to corresponding nucleic acids, such as mRNAs, to form a double-stranded molecule, which interferes with translation of the mRNA, as the cell will not translate an double-stranded mRNA. Antisense nucleic acids used in the invention are typically at least 10-12 nucleotides in length, for example, at least 15, 20, 25, 50, 75, or 100 nucleotides in length. The antisense nucleic acid can also be as long as the target nucleic acid with which it is intended that it form an inhibitory duplex. As is described further below, the antisense nucleic acids can be introduced into cells as antisense oligonucleotides, or can be produced in a cell in which a nucleic acid encoding the antisense nucleic acid has been introduced by, for example, using gene therapy methods.

Introduction of FHF antisense nucleic acids into cells affected by a proliferative disorder, for the purpose of gene therapy, can be achieved using a recombinant expression vector, such as a chimeric virus or a colloidal dispersion system, such as a targeted liposome. Those of skill in this art know or can easily ascertain the appropriate route and means for introduction of sense or antisense FHF nucleic acids, without resort to undue experimentation.

Gene therapy methods can also be used to deliver genes encoding FHF polypeptides (*e.g.*, any of FHF-1-4) to cells. These methods can be carried out to treat conditions associated with insufficient FHF expression. Thus, these methods can be used to promote tissue repair or replacement, for example, in conditions including stroke, neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, retinal degenerative diseases, such as retinitis pigmentosa and macular degeneration, and peripheral neuropathies.

Due to the high levels of expression of FHF-4 in the testes, there are a variety of applications for FHF-4-specific polypeptides, nucleic acids, and antibodies related to treating disorders of this tissue. Such applications include treatment of cell proliferative disorders related to FHF-4 expression in the testes. Various testicular developmental or acquired disorders can also be treated using FHF-4-related molecules. These conditions include, for example, viral infection (*e.g.*, viral orchitis), autoimmunity, sperm production or dysfunction, trauma, and testicular tumors. The presence of high levels of FHF-4 in the testes also suggests that FHF-4, or an FHF-4 analogue, can be used to affect male fertility.

In addition to blocking mRNA translation, oligonucleotides, such as antisense oligonucleotides, can be used in methods to stall transcription, such as the triplex method. In this method, an oligonucleotide winds around double-helical DNA in a sequence-specific manner, forming a three-stranded helix, which blocks transcription from the targeted gene. These triplex compounds can be designed to recognize a unique site on a chosen gene

(Maher, *et al.*, *Antisense Res. and Dev.*, 1(3):227, 1991; Helene, *Anticancer Drug Design*, 6(6):569, 1991). Specifically targeted ribozymes can also be used in therapeutic methods directed at decreasing FHF expression.

5 The following examples are intended to illustrate, but not to limit, the invention. While the procedures described in the examples are typical of those that can be used to carry out certain aspects of the invention, other procedures known to those skilled in the art can also be used. The following materials and methods were used in carrying out the experiments described in the examples.

MATERIALS AND METHODS

10 **Random cDNA Sequencing.** Details of retina cDNA library construction, template preparation, and sequence determination are described by Wang, *et al.*, *J. Biol. Chem.* 271, 4468-4476, 1996.

15 **Degenerate PCR.** A fully degenerate sense strand primer, with a flanking EcoRI restriction site, was synthesized to correspond to the amino acid sequence VFENYYV (SEQ ID NO:27), and three partially degenerate antisense primers, with a flanking BamHI site, were synthesized to include all possible codons for the amino acid sequence MKGN(H/R)VK (SEQ ID NO:30). These primers were used to amplify human, murine, and bovine genomic DNA templates using *T. aquaticus* polymerase under the following conditions: 1 x (94°C, 7 minutes), 35 x (45°C, 2 minutes; 72°C, 0.5 minutes; 94°C, 0.5 minutes; 95°C, 0.25 minutes). PCR products were cleaved with EcoRI and BamHI, 20 fractionated by preparative agarose gel electrophoresis, subcloned into pBluescript, and sequenced individually.

cDNA and Genomic Clones. Oligo-dT primed cDNA libraries from adult human retinas (Nathans, *et al.*, *Science* 232, 193-202, 1986) and P0-P7 mouse eyes were screened by DNA hybridization under standard conditions (see, *e.g.*, Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989). The complete coding region sequences of human FHF-1, FHF-2, and FHF-3, and mouse FHF-1, FHF-3, and FHF-4 were obtained from two independent cDNA clones. For human FHF-4, the first 72 codons were sequenced from a single clone, and the rest of the coding region was sequenced from two independent clones. For mouse FHF-2, the coding sequence was determined from cloned genomic DNA and from a PCR product obtained by amplification of the full-length, coding region from the P0-P7 mouse eye cDNA library. A partial MboI digest of a mouse genomic DNA library in bacteriophage lambda was screened to obtain the mouse FHF-2 genomic clones.

Chromosomal Localization. Human chromosome mapping was performed by Southern blot analysis of DNA obtained from a panel of 24 human-mouse or human-hamster hybrid cell lines each carrying a different human chromosome (Oncor, Gaithersburg, MD). Interspecific backcross progeny were generated by mating (C57BL/6J x *M. spretus*) F1 females and C57BL/6J males, as described (Copeland and Jenkins, *Trends Genet.* 7, 113-118, 1991). A total of 205 N2 mice were used to map the FHF loci. DNA isolation, restriction enzyme digestion, agarose gel electrophoresis, Southern blot transfer, and hybridization were performed essentially as described (Jenkins, *et al.*, *J. Virol.* 43, 26-36, 1982), using Zetabind nylon membranes (AMF-Cuno). Washing was carried out to a final stringency of 0.8 - 1.0 x SSCP, 0.1% SDS, at 65°C. The FHF-1 probe, a 1 kilobase fragment of mouse genomic DNA, detected fragments of 2.1 kilobases in C57BL/6J (B) DNA and 10.0 kilobases in *M. spretus* (S) DNA, following digestion with BamHI. The FHF-2 probe, a 0.75 kilobase fragment of mouse cDNA, detected BglI

fragments of 19.0, 11.5, 8.2, and 2.2 kilobases (B) and 13.5, 8.2, and 2.2 kilobases (S). The FHF-4 probe, a 0.3 kilobase fragment of mouse cDNA, detected EcoRV fragments of approximately 24.0 kilobases (B) and 7.7 kilobases (S).

Most of the probes and RFLPs for the loci linked to the FHF genes in the interspecific backcross have been reported earlier. These include: Irg1 and Rap2a on chromosome 14 (Lee, *et al.*, *Immunogenet.* 41, 263-270, 1995); Smst on chromosome 16 (Siracusa, *et al.*, *Genetics* 127, 169-179, 1991); and Hpvt, Cd401, and Ar on the X chromosome (Allen, *et al.*, *Science* 259, 990-993, 1993; Fletcher, *et al.*, *Genomics* 24, 127-132, 1994). The probe for apolipoprotein D (Apod), a 290 base pair HindIII / BamHI fragment of a rat cDNA that was provided by Alan Peterson, detected XbaI fragments of 3.1 and 2.8 kilobases (B) and 3.1 and 2.6 kilobases (S). The inheritance of the 2.6 kilobase *M. spretus*-specific XbaI RFLP was followed. Recombination distances were calculated as described (Green, in *Genetics and Probability in Animal Breeding Experiments* (Oxford Press, New York), pp. 77-113, 1981) using the computer program SPRETUS MADNESS. Gene order was determined by minimizing the number of recombination events required to explain the allele distribution patterns.

RNAse Protection. Total RNA was prepared from adult mouse brain, eye, heart, kidney, liver, lung, spleen, and testis by homogenization in guanidinium thiocyanate and extraction with phenol, followed by centrifugation through 5.7 M cesium chloride (Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989). Ten micrograms of total RNA from each tissue, or ten micrograms of yeast tRNA, was used for the RNAse protection assay. Riboprobes were synthesized using either T7 or T3 RNA polymerase on linearized templates that were cloned in pBluescript. Each mouse FHF probe contained 150-250 nucleotides from the antisense strand, linked to 25-50 nucleotides of

vector sequence. Reagents were obtained from Ambion (Austin, Texas), and the hybridization and digestion conditions used were as recommended by Ambion.

In Situ Hybridization. Freshly dissected adult mouse brains, whole embryos, or heads were rapidly frozen in plastic molds placed on a dry ice/ethanol slurry and processed for sectioning as previously described (Cole, *et al.*, *J. Neurochem.* 55, 1920-1927, 1990).
5 ³³P-labeled antisense riboprobes were prepared from linearized pBluescript plasmid subclones, using either T3 or T7 RNA polymerase. *In situ* hybridization was performed in 50% formamide, 0.3 M NaCl at 56°C, as described (Saffen, *Proc. Natl. Acad. Sci. USA* 85, 7795-7799, 1988). Following RNase treatment, the slides were washed for 1 hour in
10 0.1 x SSC at 55°C. After the hybridized sections were exposed to X-ray film, the slides were stained with cresyl violet. Digitized images of the stained slides and corresponding autoradiograms were superimposed using Adobe Photoshop software. The probes used were: FHF-1, 0.75 kilobase containing the complete coding region; FHF-2, 0.5 kilobase containing 0.3 kilobase of intron 4 and 0.2 kilobase of exon 5; FHF-3, two 0.4 kilobase
15 segments containing the 5' or 3' halves of the coding region; and FHF-4, 0.5 kilobase containing the 3' two-thirds of the coding region. The coding regions of the different murine FHF's share between 63% and 71% nucleotide sequence identity, suggesting that there should be little or no cross-hybridization under the conditions used.

Immunohistochemistry. Rabbit polyclonal anti-FHF-1 antibodies were raised against a
20 bacterial fusion protein consisting of the carboxyl-terminal 190 amino acids of FHF-1 fused to the T7 gene 10 protein (Studier, *et al.*, *Meth. Enzymol.* 185, 60-89, 1980). Anti-FHF-1 antibodies were affinity purified using the fusion protein immobilized on nitrocellulose as an affinity matrix, and antibodies directed against the fusion partner were removed by absorption onto immobilized T7 gene 10 protein. For immunostaining
25 of primate brain samples, three monkeys (*Macaca mulatta*) were anesthetized with

Ketamine (35 mg/kg, i.m.), injected with a lethal dose of sodium pentobarbital (100 mg/kg, i.v.), and perfused through the heart with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were removed, cryoprotected in 20% sucrose at 4°C, frozen, and cut at a thickness of 10 or 20 μ m. Sections were sequentially incubated with affinity purified-rabbit anti-FHF-1 antibodies, biotinylated goat anti-rabbit IgG (Vector), peroxidase-conjugated avidin (Extravidin, Sigma Chemical Co.), and 3,3'-diaminobenzidine dihydrochloride (Aldrich), in the presence of hydrogen peroxide. Most sections were then mounted on gelatin-coated slides, dehydrated, cleared, and covered with a cover-slip. Following the histochemical reaction, some of the 10 μ m-thick sections were washed and incubated sequentially in mouse anti-parvalbumin (Sigma), biotinylated horse anti-mouse IgG (Vector), and streptavidin conjugated to Texas Red (Chemicon). These sections were mounted on clean slides, partially dried, and covered in a glycerol/phosphate buffer medium. Adjacent sections were processed histochemically for cytochrome oxidase or were stained for Nissl substance, to determine the boundaries of subcortical nuclei or cortical areas and layers.

Production and Localization of FHF-1 in Transfected Cells. To increase the efficiency of FHF-1 translation, the region immediately 5' to the initiator methionine coding sequence was converted to an optimal ribosome binding site (CCACCATGG) by PCR amplification, before inserting the complete FHF-1 open reading frame into the eukaryotic expression vector pCIS (Gorman, *et al.*, *DNA Protein Eng. Tech.* 2, 3-10, 1990). The pCIS vector was also used for the beta-galactosidase constructs. Human embryonic kidney cells (293 cells) were transiently transfected with the expression construct and a plasmid expressing the simian virus 40 (SV40) large T-antigen (pRSV-TAg) using the calcium phosphate method (Gorman, *et al.*, *supra*). For ³⁵S-methionine labeling, cells were transferred to serum-free medium 24 hours after transfection, and labeled for 6 hours. For immunostaining, transfected cells were grown

on gelatin-coated coverslips. One day after transfection, the cells were fixed in 2% formaldehyde in PBS for 30 minutes at room temperature, permeabilized with cold methanol for 10 minutes at -20°C, preincubated for 15 minutes in 3% BSA in phosphate-buffered saline (PBS), incubated for 1 hour at room temperature with affinity purified
5 anti-FHF-1 antibody at a dilution of 1:1000 and mouse monoclonal anti-BiP at a dilution of 1:400 in 3% BSA in PBS, washed 3 x 15 minutes with 0.1% TWEEN-20™ in PBS at room temperature, and then incubated with fluorescein-conjugated donkey anti-rabbit IgG and rhodamine-conjugated goat anti-mouse IgG in 3% BSA in PBS for 30-60 minutes. The coverslips were then washed in 0.1% TWEEN-20™ in PBS and mounted in 0.1%
10 1,4-diazobicyclo-[2,2,2]-octane (DABCO), 75% glycerol, 10 mM Tris, pH 8.0. For X-gal staining, transfected cells were fixed in 0.5% glutaraldehyde/PBS for 10 minutes at room temperature, washed twice in PBS with 2 mM MgCl₂, incubated in 1 mg/ml 5 mM K₃Fe(CN)₆, 5 mM K₄Fe(CN)₆, 2 mM MgCl₂ in PBS for 1-2 hours at 37°C and postfixed in 0.5% glutaraldehyde in PBS for 10 minutes at room temperature.

EXAMPLE 1
IDENTIFICATION OF FIBROBLAST GROWTH FACTOR
HOMOLOGOUS FACTORS (FHF_s)

To identify gene products expressed in the human retina, random segments of human
5 retina cDNA clones were partially sequenced, and the resulting partial sequences were
compared to sequences in publicly available databases. In detail, an adult human retina
cDNA library constructed in lambda gt10 (Nathans, *et al.*, *Science*, 232:193, 1986) was
amplified, and the cDNA inserts were excised *en mass* by cleavage with EcoRI and
purified from the vector by agarose gel electrophoresis. Following heat denaturation of
10 the purified cDNA inserts, a synthetic oligonucleotide having an EcoRI site at its 5' end
and six random nucleotides at its 3' end
(5'-GACGAGATATTAGAATTCTACTCGNNNNNN-3'; (SEQ ID NO:32)) was used to
prime two sequential rounds of DNA synthesis in the presence of the Klenow fragment of
E. Coli DNA polymerase. The resulting duplex DNA molecules were amplified by the
15 polymerase chain reaction (PCR) using a primer corresponding to the unique 5' flanking
sequence (5'-CCCCCCCCCGACGAGATATTAGAATTCTACTCG-3'; (SEQ ID
NO:33)). The PCR products, representing a random sampling of the original cDNA
inserts, were cleaved with EcoRI, size fractionated by preparative agarose gel
electrophoresis to include only segments of approximately 500 base pairs in length, and
20 cloned into lambda gt10. Three thousand single plaques from this library were arrayed in
96-well trays and the inserts from these clones were amplified by PCR and then
sequenced using the dideoxy method and automated fluorescent detection (Applied
Biosystems). A single sequencing run from one end of each insert was conceptually
translated for both strands, in all three reading frames, and the six resulting amino acid
25 sequences were used to search for homology in the GenBank nonredundant protein
database using the BLASTX searching algorithm.

One partial cDNA sequence was identified that showed statistically significant homology to previously described members of the FGF family. Using this partial cDNA as a probe, multiple, independent cDNA clones were isolated from the human retina cDNA library, including two clones that encompass the entire open reading frame, and from which
5 complete nucleotide sequences were determined. The complete nucleotide sequence encodes a novel and highly divergent member of the FGF superfamily, and was designated fibroblast growth factor homologous factor-1 (FHF-1). The deduced amino acid sequence of FHF-1 contains 244 amino acids and is 27% identical to FGF-9, which is the member of the FGF family that shares the most homology with FHF-1. The
10 nucleotide and deduced amino acid sequences of FHF-1 are shown in Figure 5.

The FHF-1 sequence was used to search the National Center for Biotechnology Information (NCBI) database of expressed sequence tags (ESTs) and sequence tagged sites (STSs). One EST entry (DBEST ID 06895), derived from a human infant brain cDNA library (Adams, *et al.*, *Nature Genet.* 4, 373-380, 1993) encoded a segment of 77
15 amino acids having significant homology to the carboxyl-terminus of FHF-1, but no significant homology to other members of the FGF family. The polypeptide containing this amino acid segment was designated FHF-2. One STS entry (DBEST ID 76387; Brody, *et al.*, *Genomics* 25, 238-247, 1995), derived from human genomic DNA contained a putative exon encoding a protein segment with a high degree of homology to
20 FHF-1 and a low degree of homology to other FGF family members. The polypeptide containing this amino acid segment was designated FHF-3. Full-length FHF-2 and FHF-3 cDNA clones were isolated from an adult human retina cDNA library, and were found to encode proteins of 245 and 225 amino acids, respectively, each having greater than 58% amino acid identity to FHF-1 and to each other. The nucleotide and deduced
25 amino acid sequences of FHF-2 and FHF-3 are shown in Figure 6 and Figure 7, respectively.

A comparison of the sequences of FHF-1, FHF-2, and FHF-3 revealed several regions of high amino acid sequence conservation, and two of these regions were used to design degenerate oligonucleotide primers for use in PCR. The primers have sequences that correspond to codons for the conserved amino acids at their 3' ends (at residues 151-157 and 184-190 in the FHF-1 sequence (SEQ ID NO:1); see Figure 5, and below), and restriction enzyme cleavage sites at their 5' ends, to facilitate cloning of the resulting PCR products. A full degenerate sense strand primer with a flanking EcoRI restriction site was synthesized for the amino acid sequence VFENYYV (SEQ ID NO:27; amino acids 151-157) (5'-CCGATCGAATTCGTNTT(T/C)GA(A/G)AA(T/C)TA(T/C)TA(T/C)GT-3'; SEQ ID NO:34). Three partially degenerate antisense primers with a flanking BamHI site were synthesized to include all possible codons for the amino acid sequence MKGN(H/R)VK (SEQ ID NO:30; amino acids 184-190) (5'-GCGATCGGATCCTTNAC(A/G)TG(A/G)TTNCC(T/C)TTCAT-3' (SEQ ID NO:35); 5'-GCGATCGGATCCTTNAC(T/C)CT(A/G)TTNCC(T/C)TTCAT-3' (SEQ ID NO:36); and 5'-GCGATCGGATCCTTNACNCG(A/G)TTNCC(T/C)TTCAT-3' (SEQ ID NO:37)). The three pairs of sense and anti-sense primers were used in PCR reactions containing human, murine, and bovine genomic DNA templates and *Thermus aquaticus* DNA polymerase and the reactions were carried out under the following conditions: 1 x (94°C, 7 minutes), 35 x (45°C, 2 minutes; 72°C, 0.5 minutes; 94°C, 0.5 minutes; 95°C, 0.25 minutes). PCR products were cleaved with EcoRI and BamHI, fractionated by preparative agarose gel electrophoresis, subcloned into pBluescript, and individually sequenced. Analysis of the amplification products obtained using mouse, human, and bovine genomic DNA templates revealed that, in each of these species, this region of FHF-1, FHF-2, and FHF-3 is encoded within a single exon. This analysis also revealed a fourth class of FHF-like PCR products which was present in all

three species and was found to encode an FHF-like protein, designated FHF-4. The PCR product corresponding to FHF-4 was used as a probe to isolate full-length cDNA clones from a human retina cDNA library and a developing mouse eye cDNA library. A protein of 247 amino acids having greater than 60% amino acid identity to FHF-1, FHF-2, and FHF-3, is predicted to be encoded by these clones. The nucleotide and deduced amino acid sequence of FHF-4 is shown in Figure 8.

Figure 3 shows an alignment of the amino acid sequences of identified FHFs and previously characterized and published FGFs (1-9) and Figure 4 is a dendrogram of the identified FHFs and all the published FGF sequences. Pairwise comparisons between each FHF and the nine FGF family members show less than 30% amino acid sequence identity, while all pairwise comparisons among the four FHFs show between 58% and 71% amino acid sequence identity. Between mouse and human orthologues, there is greater than 97% amino acid sequence identity. The murine FHFs differ from their human orthologues by the amino acid substitutions listed below. The first and last letters indicate the amino acids in the human and mouse sequences, respectively, and the number indicates the position along the polypeptide chain: FHF-1: Q86E; FHF-2: A2T, L136H; FHF-3: A58T, P60Q, Q180R, L197V, Q207R, A217T, P225H; and FHF-4: C40F, A181V, P221A, S244C. Thus, the four FHFs define a distinct and highly conserved branch of the FGF family.

FHFs 1-4 each lack a recognizable amino-terminal signal sequence. Among the nine previously characterized members of the FGF family, FGF-1, FGF-2, and FGF-9 are also distinguished by lacking a recognizable amino-terminal signal sequence (Abraham, *et al.*, *Science* 233, 545-548, 1986; Jaye, *et al.*, *Science* 233, 541-545, 1986; Miyamoto, *et al.*, *Mol. Cell Biol.* 13, 4251-4259, 1993). Current evidence indicates that FGF-1 and FGF-2 are synthesized in the cytosol and are released by a mechanism independent of the

ER-Golgi secretory pathway (Florkiewicz, *et al.*, *J. Cell Physiol.* 162, 388-399, 1995; Jackson, *et al.*, *J. Biol. Chem.* 270, 33-36, 1995). Although FGF-9 lacks a cleavable amino-terminal signal sequence, it is glycosylated and is efficiently secreted from cultured glioma, Chinese hamster ovary, and COS cells, presumably via the ER-Golgi pathway (Miyamoto, *et al.*, *Mol. Cell Biol.* 13, 4251-4259, 1993).

EXAMPLE 2

DEDUCED AMINO ACID SEQUENCE OF FHF-4

Figure 8 shows the nucleotide and deduced amino acid sequences of human FHF-4, which was derived from the human retina cDNA clones described above. As is mentioned above, the primary translation product of the human FHF-4 gene is predicted to be 247 amino acids in length. The human FHF-4 initiator methionine codon shown in Figure 8 at nucleotide positions 78-80 and is the first in frame ATG; a good consensus ribosome binding site (CCACCATGG; Kozak, *Nucleic Acids Res.*, 15:8125, 1987) is found at this position. This choice of ATG conforms to the sites of translation initiation in FHF-1, FHF-2, and FHF-3, as shown in the alignment in Figure 1. The next methionine codon in the FHF-4 open reading frame is located 85 codons 3' to the putative initiator methionine codon. Similar to FGF-1 and FGF-2, as well as FHF-1-3, FHF-4 lacks a discernable amino-terminal signal sequence. Human FHF-4 has a single Asn-Lys-Ser motif at amino acids 242-244, which conforms to the consensus sequence for asparagine-linked glycosylation, but this site is not conserved in the highly homologous mouse FHF-4 sequence (see Figure 3), suggesting that it may not be used for glycosylation.

EXAMPLE 3

CHROMOSOMAL LOCALIZATION OF FHF GENES

In humans, FHF-1, FHF-2, FHF-3, and FHF-4 are located on chromosomes 3, X, 17, and 13, respectively. The chromosomal locations of FHF-1, FHF-2, and FHF-4, were
5 determined by Southern blot hybridization of genomic DNA from rodent-human hybrid cell lines carrying individual human chromosomes. For example, in the case of human FHF-4, a Southern blot containing restriction enzyme-digested DNA from a panel of 24 human-mouse and human-hamster cell line, each containing a different human chromosome (Oncor, Gaithersburg, Maryland). Hybridization of a human FHF-4 probe
10 to human, mouse, and hamster genomic DNA produced distinct hybridizing fragment sizes. Among the hybrid panels, the human-specific hybridization pattern was seen in the lanes corresponding to the hybrid cell line carrying human chromosomes 1 and 13, suggesting that one of these cell lines contains additional genomic sequences derived from the chromosome present in the other cell line. To determine which of these two
15 human chromosomes contained the FHF-4 gene, the location of the mouse gene was determined by interspecific backcross mapping. As discussed further below, this analysis located the FHF-4 gene on mouse chromosome 14, less than 1 cM from the Rap2a gene, and within a region that is syntenic with human chromosome 13q34. Taken together, these data show that in humans, the FHF-4 gene maps to chromosome 13. The FHF-3
20 locus is on human chromosome 17, as the STS described above that encompasses one exon of FHF-3 was derived from human chromosome 17 and maps near the BRCA-1 gene (Brody, *et al.*, *Genomics* 25, 238-247, 1995).

The chromosomal locations of FHF-1, FHF-2, and FHF-4 in the mouse were determined using an inter-specific backcross mapping panel from crosses of (C57BL/6J x *Mus*
25 *spretus*), F1 x C57BL/6J. This mapping panel has been typed for over 2100 loci, which

are well distributed over all 19 mouse autosomes and the X-chromosome (Copeland and Jenkins, *Trends Genet.* 7, 113-118, 1991). C57BL/6J and *M. spretus* DNAs were digested with several restriction enzymes and analyzed by Southern blot hybridization for informative RFLPs. The chromosomal location of each locus was determined by comparing its strain distribution in the backcross mice with the strain distribution patterns for all other loci already mapped in the backcross (Figure 9). FHF-1 mapped to the proximal region of mouse chromosome 16, 1.6 cM distal to Smst and 5.1 cM proximal to Apod. FHF-2 mapped to the X chromosome, and did not recombine with Cd401 in 168 mice typed in common, suggesting that the two loci are within 1.8 cM of each other (upper 95% confidence interval). As is mentioned above, FHF-4 mapped to the distal region of chromosome 14, and did not recombine with Rap2a in 142 mice typed in common, suggesting that the two loci are within 2.1 cM of each other. The FHF-3 gene was not mapped with the backcross panel, as it did not reveal an informative RFLP when tested with 14 restriction enzymes. The proximity of the human FHF-3 gene to BRCA-1 suggests that the mouse FHF-3 gene resides on chromosome 11 in the region that is syntenic with the BRCA-1 region of human chromosome 17. The FHF genes map in regions of the composite mouse linkage map (Mouse Genome Database, Jackson Laboratory, Bar Harbor, Maine), which contains a number of mutations that may be candidate FHF alleles.

EXAMPLE 4

TISSUE AND SUBCELLULAR DISTRIBUTIONS OF FHF RNAs

Expression Patterns of FHFs in the Mouse. The tissue distributions of transcripts derived from each of the four identified FHF genes were determined in RNase protection experiments. Analysis of RNA prepared from brain, eye, heart, kidney, liver, lung, spleen, and testis revealed that each FHF is expressed in the brain, and FHF-1, FHF-2,

and FHF-3 are expressed in the eye, FHF-1 and FHF-4 are expressed in the testis, and FHF-2 is expressed in the heart (Figure 10). In the brain, FHF-2 transcripts are at least five-fold more abundant than the transcripts from any of the other FHFs.

The patterns of FHF gene expression during development were studied by *in situ* hybridization experiments using sections obtained on gestational day 11 (e11), gestational day 17 (e17), postnatal day 1 (P1), and from adults. FHF-2 transcripts are abundant at each of the time points examined, and are present in all divisions of the central and peripheral nervous systems, including the enteric nervous system (Figures 11A, 11C, 11D, and 11F). Consistent with the RNase protection experiments, FHF-2 transcripts were observed in the developing heart at e17 (Figure 11D). FHF-1, FHF-3, and FHF-4 transcripts were also observed to be widely distributed throughout the developing nervous system (Figures 11B and 11E). For example, at P1, FHF-1 was found to be highly expressed in the retina, olfactory epithelium, and olfactory bulb (Figure 11E). At e11, FHF-1 and FHF-3 were also found in a segmental pattern in the body wall (Figure 11B). In the adult brain, each FHF showed a distinct pattern of expression: FHF-1 transcripts were present at high levels in the olfactory bulb, and at lower levels in the cerebellum, the deep cerebellar nuclei, throughout the cortex, and in multiple midbrain structures (Figure 11G); FHF-2 transcripts were most abundant in the hippocampus and were present at lower levels in multiple brain areas (Figures 11H and 11I); FHF-3 transcripts were present in the olfactory bulb, hippocampus, and cerebellum, where they were most concentrated in the Purkinje cell layer (Figure 11J); and FHF-4 transcripts are present at high levels throughout the granular layer of the cerebellum, and at lower levels in the hippocampus and olfactory bulb (Figures 11K and 11L).

Distribution of FHF-1 Immunoreactivity in Monkey Brain. The distribution of FHF-1 immunoreactivity in adult rhesus monkey brain was examined using affinity

purified polyclonal anti-FHF-1 antibodies. These antibodies bind to recombinant FHF-1, but do not bind to recombinant FHF-2, as was determined by immunostaining of transfected 293 cells and by Western blotting. Although immunoreactivity with these antibodies is referred to as 'FHF-1 immunoreactivity' the possibility exists that other members of the FHF family are in part responsible for the observed immunostaining.

FHF-1 immunoreactive somata are present throughout the rhesus monkey cerebral cortex, but they are unevenly distributed across layers in any one area and display marked variations in density and distribution across functional areas (Figures 12A-12E). The low magnification photomicrographs in Figure 12 show that in primary visual, somatosensory, and auditory areas, a relatively high density of immunostained cells is present and that these cells occupy predominantly the middle layers. In contrast, fewer and more widely scattered immunostained neurons are present in the precentral motor area and in the association cortex of the superior parietal lobule.

Common to each of these cortical areas is the presence of several FHF-1 immunoreactive populations, the most prominent of which have relatively large (12-14 μm diameter), intensely immunoreactive somata. Other neurons with smaller (8-10 μm diameter) and more lightly immunostained somata are also present in all areas (Figure 12F). Co-localization experiments demonstrated that the FHF-1 immunoreactive neurons in the cerebral cortex make up a subpopulation of neurons that are immunoreactive for the calcium-binding protein, parvalbumin (Figures 12G and 12H), which have previously been shown to make up a subset of gabanergic interneurons in the monkey cerebral cortex (Hendry, *et al.*, *Exp. Brain Res.* 76, 467-472, 1989). Variations in immunostained cell density were also seen in the hippocampal formation, where intensely immunoreactive somata were relatively common in the subicular complex, but were widely scattered in the CA fields, the dentate hilus, and the dentate gyrus (Figure 12I).

A different pattern of FHF-1 immunostaining was seen in the dorsal thalamus (Figure 12J). Only a few of the many nuclei in this region contained immunoreactive neurons; most prominent among them was the principal somatosensory relay nucleus (the caudal ventroposterolateral nucleus, VPLc) and the visual relay nucleus (the lateral geniculate nucleus, LGN). In the LGN, both magnocellular and parvicellular layers are equally immunostained. Figure 12J shows that in the LGN, ipsilateral to an eye deprived by occlusion since birth, FHF-1 immunostaining was markedly lower in layers innervated by the deprived eye than in layers innervated by the normal eye.

The relatively large sizes of the FHF-1 immunostained somata in nuclei of the dorsal thalamus suggests they are cell bodies of neurons that send their axons to the cerebral cortex. Localization of FHF-1 immunoreactivity in neurons of VPLc and LGN that are lightly immunoreactive for parvalbumin supports this conclusion, since these parvalbumin immunostained neurons in dorsal thalamus have been shown to be thalamocortical neurons (Jones and Hendry, *Eur. J. Neurosci.* 1, 222-246, 1989).

Outside of the dorsal thalamus, FHF-1 immunoreactive neurons were present in a diverse collection of subcortical nuclei, including the globus pallidus and putamen, red nucleus, substantia nigra, and third nerve complex (Figure 12K). In addition, large cells in the deep layers of both the superior and inferior colliculi were immunostained, as were neurons in the deep cerebellar nuclei. In conclusion, FHF-1 immunoreactivity was broadly distributed across the neuraxis, but at each level it was present in subsets of neurons.

Subcellular Localization of FHF-1 in Transfected Cells. As noted above, of the nine FGFs described prior to this report, FGF-1 and FGF-2 are distinguished by lacking of an amino terminal signal sequence and by secretion via a pathway that is independent of the

ER and Golgi apparatus (Florkiewicz, *et al.*, *J. Cell Physiol.* 162, 388-399, 1995; Jackson, *et al.*, *J. Biol. Chem.* 270, 33-36, 1995). Moreover, FGF-1 and a subset of FGF-2 isoforms, produced by alternative translation initiation, have been shown to accumulate in the nuclei of the cells in which they are synthesized, as well as in the nuclei of target cells (Imamura, *et al.*, *Science* 249, 1567-1570, 1990; Imamura, *et al.*, *J. Biol. Chem.* 267, 5676-5679, 1992; Bugler, *et al.*, *Molec. Cell Biol.* 11, 573-577, 1991; Zhan, *et al.*, *Biochem. Biophys. Res. Comm.* 188, 982-991, 1992; Cao, *et al.*, *J. Cell Science* 104, 77-87, 1993; Wiedlocha, *et al.*, *Cell* 76, 1039-1051, 1994). These proteins contain a nuclear localization signal (NLS) that conforms closely to a consensus NLS. The nuclear accumulation of FGF-1 and FGF-2 has raised the possibility that these proteins have modes of action in addition to those mediated by binding and activating cell surface receptors.

Like FGF-1 and FGF-2, each of the four identified FHF's lacks a classical signal sequence and contains clusters of basic residues near its amino terminus that could serve as an NLS. These observations suggest that FHF's may resemble FGF-1 and FGF-2 in their mechanism of secretion and in their subcellular localization. To test this possibility, the fate of FHF-1 synthesized in transiently transfected 293 cells, which are human embryonic kidney cells, was determined. In one set of experiments, biosynthetically labeled FHF-1 was found to accumulate to high levels intracellularly, but was not detectably secreted into the medium (Figure 13). In contrast, human growth hormone produced in parallel transfections was efficiently secreted (Figure 13). As 293 cells can secrete a wide variety of growth factors through the ER-Golgi pathway, this experiment is consistent with the proposal that FHF's are not secreted via this route.

In a second set of experiments, immunostaining of transfected 293 cells revealed accumulation of FHF-1 in the nucleus, suggesting that the clusters of basic residues can

function as an NLS. A similar result was obtained with FHF-2. Two main classes of NLS motifs have been described, the classical and bipartite motifs (Boulikas, *Crit. Rev. Eukaryotic Gene Expression* 3, 193-227, 1993). The classical NLS contains a cluster of six lysine or arginine amino acids, and the bipartite NLS contains two clusters of three or four basic amino acids separated by a ten amino acid spacer. In FHF-1 the clusters of basic amino acids resemble more closely the bipartite NLS consensus. To identify and characterize the putative FHF-1 NLS, we determined the subcellular localization of deletion mutants of FHF-1 by immunostaining with anti-FHF-1 antibodies, and of fusions between FHF-1 and β -galactosidase by X-gal staining. These experiments show that the two clusters of arginines and lysines at amino acids 11-18 and 28-38 in FHF-1 make up the two basic regions of a bipartite NLS. In the context of the FHF-1 protein, deletion of either cluster produced a modest increase in the level of cytoplasmic FHF-1, but left significant nuclear accumulation (constructs 2 and 3; Figure 14), while deletion of both regions abolished nuclear accumulation (construct 4; Figures 14 and 15). To further characterize the minimal region required for import, the first 56 or the first 69 residues of FHF-1 were fused to beta-galactosidase and were shown to contain a functional NLS (constructs 5 and 6; Figures 14 and 15). Fusion of FHF-1 amino acids 1-22 or 23-55 individually to beta-galactosidase failed to direct nuclear localization, indicating a requirement for both parts of the bipartite NLS or a requirement for sequences distal to the first 55 residues. With beta-galactosidase fused to the first 69 amino acids of FHF-1, the results of a deletion analysis resembled those seen with intact FHF-1 (constructs 5, 9, 10, and 11; Figures 14 and 15). Finally, fusion of FHF-1 amino acids 11-38, containing only the two clusters of basic amino acids separated by a 10 amino acid spacer, conferred nuclear localization, although less efficiently than the larger segments that contained this region, suggesting that amino acids 1-10 or 56-68, outside of the bipartite NLS consensus, play an ancillary role in nuclear localization.

It is to be understood that, while the invention has been described with reference to the above detailed description, the foregoing description is intended to illustrate, but not to limit, the scope of the invention. Other aspects, advantages, and modifications of the invention are within the scope of the following claims. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

5